Stock Markets July 1, 2026 04:23 PM

Alibaba, U.S. Payment Processor to Pay $600 Million Under DOJ Settlement Over Illegal Drug Sales

Non-prosecution agreements resolve claims that platforms and payment services failed to stop shipments of illegal pharmaceuticals, chemicals and counterfeiting equipment into the U.S.

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn

Alibaba Group and its U.S.-based payment processor, AUS Merchant Services, agreed to pay $600 million and enter non-prosecution agreements with the U.S. Department of Justice after admitting they did not adequately prevent the sale and importation of illegal drugs, related chemicals and pill presses through Alibaba’s e-commerce channels. The Justice Department said the failures occurred between 2016 and 2024 and involved roughly 80,000 illicit product sales with combined merchandise value exceeding $200 million.

Alibaba, U.S. Payment Processor to Pay $600 Million Under DOJ Settlement Over Illegal Drug Sales
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Alibaba Group and its U.S.-based payment processor, AUS Merchant Services, agreed to pay $600 million and entered into non-prosecution agreements with the U.S. Department of Justice.
  • The Justice Department said Alibaba admitted that from 2016 to 2024 it failed to prevent about 80,000 sales of chemicals, drugs and pharmaceutical counterfeiting equipment imported from overseas, with a combined merchandise value of more than $200 million.
  • Law enforcement conducted over 40 undercover purchases of illegal pharmaceuticals and counterfeiting equipment during the investigation; both companies accepted responsibility for the actions of their officers and employees and pledged to improve compliance programs.

The U.S. Department of Justice announced on Wednesday that Alibaba Group and a U.S.-based payments firm, AUS Merchant Services, have reached a settlement totaling $600 million to resolve allegations tied to illegal drug sales and the importation of related equipment. The companies entered into non-prosecution agreements addressing claimed violations of the Federal Food, Drug, and Cosmetic Act.

According to the Justice Department, the core of the case focused on the inability of Alibaba and its payment processor to prevent merchants from listing, selling and arranging imports of illegal pharmaceuticals, chemical substances and pill presses via Alibaba’s e-commerce platforms. In the settlement, both companies agreed to accept responsibility for the conduct of their officers and employees and committed to enhancing their compliance programs.

The department said Alibaba acknowledged that, over the period from 2016 to 2024, it failed to stop roughly 80,000 product sales involving chemicals, drugs and pharmaceutical counterfeiting equipment that entered the United States from overseas sellers. The transactions identified in the investigation had a combined merchandise value of more than $200 million, the Justice Department said.

Investigators carried out more than 40 undercover purchases of illegal pharmaceuticals and counterfeiting devices as part of the inquiry. The undercover buys were cited by the Justice Department in describing the scope of the activity it investigated.

As part of the resolution, Alibaba and AUS Merchant Services accepted accountability for internal actions tied to the offenses and pledged to improve compliance measures. The non-prosecution agreements are the legal mechanism used to resolve the claims without pursuing criminal charges, contingent on the companies meeting the terms set by the Justice Department.

The settlement and the admitted failures highlighted by the Justice Department center on enforcement of U.S. regulatory protections intended to keep illegal and potentially dangerous drugs and manufacturing equipment out of the country. The announced payment and compliance commitments conclude the department’s action as described in its statement on Wednesday.


Context and next steps

The Justice Department’s announcement resolves its claims through financial payment and formal agreements requiring remedial steps by the companies. The settlement text, as summarized by the department, emphasizes both the monetary component and the expectation that Alibaba and its payment processor bolster systems designed to prevent illicit listings and shipments.

Risks

  • Regulatory enforcement risk for e-commerce platforms and payment processors related to the sale and importation of illegal pharmaceuticals and equipment - impacts the e-commerce and payments sectors.
  • Reputational and compliance risk for companies operating marketplace platforms if internal controls and merchant monitoring are inadequate - impacts corporate governance and investor sentiment in technology and online retail sectors.
  • Operational uncertainty over the implementation and effectiveness of enhanced compliance programs required by the settlement - impacts compliance, legal and logistics functions within affected companies.

More from Stock Markets

AeroVironment Secures $500 Million Contract for Counter-UAS Capabilities Jul 1, 2026 Colombian shares slip as Financials, Investment and Public Services lag; COLCAP down 0.41% Jul 1, 2026 Dan Ives Departs Wedbush to Form AI-Focused Merchant Bank Jul 1, 2026 Moscow stocks close modestly lower as energy, mining and power drag index down Jul 1, 2026 Bridgewater’s Pure Alpha posts 8.1% H1 gain as markets rebound from volatility Jul 1, 2026